You are here

Novosanis has received a CE-mark for their Colli-Pee ® with special preservative solution for oncology research applications.
The monkeypox (MPX) outbreak is an evolving global health threat. WHO and the Biden administration have declared the outbreak a global health emergency and public health emergency ,...
Novosanis launches Colli-Pee containing UAS Large Volumes offering a new solution for oncology research
Today, Novosanis has launched its novel solution for oncology research applications. Together with our sister company DNA Genotek, we have developed a novel stabilization chemistry, UAS TM...
It is well-established that Human Papillomavirus (HPV), the primary cause of cervical cancer can be detected in first-void urine. The study by Laura Téblick (University of Antwerp, Belgium...
We recently had the opportunity to interview Dr. Severien Van Keer, a post-doc researcher at the VAXINFECTIO research group, at the University of Antwerp.
CE-IVD marked
Novosanis achieved two major milestones - our Colli-Pee ® Small Volumes product line is now CE-Marked.
Novosanis attended IUSTI2018 from June 26 to June 30 in Dublin, Ireland. Our Colli-Pee device suited for first-void urine collection allowing for improved detection of STIs was on display...
Colli-Pee US FDA listed
Prostate cancer is the most common male cancer, with around 400,000 new cases every year in Europe.
For a healthy life
Urology week is an initiative from the European Association for Urology (EAU) that tries to raise awareness for urological care and its importance in improving quality of life.
This is the story of Michele Baldwin, a 45-year-old mother of three who was diagnosed with late-stage cervical cancer.